PGEN - Precigen Inc logo

Precigen Inc

PGEN

Precigen, Inc. develops gene and cell therapies focused on immuno-oncology, autoimmune disorders, and infectious diseases. Its platforms include AdenoVerse for gene delivery and UltraCAR-T for chimeric antigen receptor T cell therapies for cancer.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$235today

Score Overview

1 Year
Score
Net Growth37.08%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth8x
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.2
Net Growth-71.11%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth6x
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth15.49%
Net Trend50%
Net Income Consistency
Rev Growth-55.10%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-304.58%
Net Trend38%
Net Income Consistency
Rev Growth260.76%
Rev Trend54%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Precigen Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. PGEN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 6.19โ€”
1 Year2025-10-23
$ 4.2545.65%
5 Years2021-10-22
$ 4.5934.86%
10 Years2016-10-21
$ 26.39-76.55%
All Time2013-08-08
$ 23.63-73.81%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 85M-$ 157M$ 38M
2025$ 9M-$ 250M$ 97M
2024$ 3M-$ 126M$ 97M
2023$ 6M-$ 95M$ 62M
2022$ 26M$ 28M$ 55M
2021$ 14M-$ 92M$ 108M
2020$ 31M-$ 170M$ 100M
2019$ 31M-$ 170M$ 75M
2018$ 160M-$ 509M$ 222M
2017$ 230M-$ 117M$ 79M
2016$ 190M-$ 186M$ 237M
2015$ 173M-$ 84M$ 238M
2014$ 71M-$ 81M$ 115M
IPO2013$ 23M-$ 38M$ 177M
PGEN - Precigen Inc logo

Precigen Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 31M to $ 9M and net income went from -$ 170M to -$ 250M. Revenue increased in 3 of those 5 years; net income in 2.

Between 2015 and 2025, revenue declined from $ 173M to $ 9M and net income went from -$ 84M to -$ 250M. Revenue increased in 4 of those 10 years; net income in 5.

Precigen Inc currently holds a 5-year HDB Score of 4.2 out of 10. How the HDB Score is calculated.

Membership

Explore PGEN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies